4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to

WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera's SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies (mAbs) into subcutaneous (SQ) formulations. Comera's SQore platform

WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares are accompanied by five-year warrants to purchase shares of common stock at an exercise price of $0.6135 per share. On July 31, 2023, Comera sold and issued a total of 4,399,016 shares of its common st

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine's viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formula

– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™ patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera's SQore platform and significantly broaden claims covered by previously issued patents. "We have expanded and strengthened our robust global patent portfolio

WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares are accompanied by five-year warrants to purchase shares of common stock at an exercise price of $0.6135 per share, beginning six months and one day after issuance. On July 31, 2023, Comera s

– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) --  Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – – Joined the Subcutaneous Drug Development & Delivery Consortium (SC Consortium) to advance the science, technology, and best practices for subcutaneous (SQ) drug development and delivery – WOBURN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the quarter ended September 30, 2022 and provided a business update. "We are extremely pleased with our progress this quarter. We have made s

WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022.    "This has been a historic year for Comera, as we have transitioned into a public company, completed a significant collaboration with Intas, and made important progress in strengthening our team and capabilities. These advancements have us well positioned to execute on our long-term strategy to leverage our SQore™ platform," said Jeff Hackman, Preside

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please

WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te

Gainers Comera Life Sciences (NASDAQ:CMRA) stock increased by 11.6% to $0.28 during Friday's after-market session. The company's market cap stands at $8.5 million. The company's, Q3 earnings came out yesterday. SenesTech (NASDAQ:SNES) stock rose 9.51% to $0.26. As per the press release, Q3 earnings came out yesterday. Aravive (NASDAQ:ARAV) stock rose 9.44% to $0.14. Aravive's trading volume hit 68.8K shares by close, accounting for 0.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 8.67% to $2.13. The market value of their outstanding shares is at $1.2 million. Co

Comera Life Sciences (NASDAQ:CMRA) reported quarterly losses of $(0.10) per share. This is a 50 percent increase over losses of $(0.20) per share from the same period last year. The company reported $136.31 thousand in sales this quarter. This is a 41.98 percent decrease over sales of $234.92 thousand the same period last year.

Gainers LianBio (NASDAQ:LIAN) shares moved upwards by 128.1% to $3.17 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 77.9 million, which is 39428.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $339.7 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 45.24% to $0.44. Trading volume for this security as of 13:31 EST is 41.4 million, which is 1166.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.3 million. ImmunityBio (NASDAQ:IBRX) shares increased by 27.92% to $1.83. The current volume of 21.9 million shares is 827.8% of Immunity

Gainers Lipella Pharmaceuticals (NASDAQ:LIPO) stock increased by 43.5% to $2.31 during Friday's pre-market session. The company's market cap stands at $13.4 million. Aravive (NASDAQ:ARAV) stock increased by 17.18% to $0.17. The company's market cap stands at $12.1 million. American Well (NYSE:AMWL) stock rose 16.56% to $1.1. The company's market cap stands at $313.1 million. Akso Health Group (NASDAQ:AHG) stock rose 11.99% to $1.4. The company's market cap stands at $32.0 million. Comera Life Sciences (NASDAQ:CMRA) stock increased by 11.46% to $0.3. The market value of their outstanding shares is at $9.1 million. 180 Life Sciences (NASDAQ:ATNF) shares increased by 11.24% to $0.5. The m

Gainers American Well (NYSE:AMWL) stock moved upwards by 22.9% to $1.16 during Thursday's after-market session. American Well's trading volume hit 1.3 million shares by close, accounting for 101.4% of its average volume over the last 100 days. The company's market cap stands at $330.2 million. Comera Life Sciences (NASDAQ:CMRA) stock rose 12.73% to $0.3. The market value of their outstanding shares is at $9.2 million. Generation Bio (NASDAQ:GBIO) stock rose 10.83% to $1.33. Trading volume for this security closed at 62.0K, accounting for 38.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $87.6 million. Applied Molecular (NASDAQ

Gainers Biocept, Inc. (NASDAQ:BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Shift Technologies, Inc. (NASDAQ:SFT) shares rose 74.4% to $0.1878 in pre-market trading. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares gained 45% to $2.45 in pre-market trading after gaining around 4% on Tuesday. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares climbed 41.2% to $0.0720 in pre-market trading after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12,

Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares rose 60.6% to $0.63 during Friday's regular session. Bio-Path Hldgs's stock is trading at a volume of 111.1 million shares as of 13:30 EST. This is 15820.7% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million. Processa Pharma (NASDAQ:PCSA) stock moved upwards by 22.69% to $0.41. The current volume of 5.1 million shares is 2367.4% of Processa Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $9.9 million. Harpoon Therapeutics (NASDAQ:HARP) stock increased by 20.66% to $3.97. As of 13:30 EST, Harpoon Therapeutics's stock is trad

Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock increased by 158.8% to $1.02 during Thursday's after-market session. Today's trading volume for this security ended up closing at 18.9 million shares, which is 5623.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.6 million. Comera Life Sciences (NASDAQ:CMRA) shares increased by 63.0% to $0.52. At the close, Comera Life Sciences's trading volume reached 572.6K shares. This is 1127.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $15.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.02% to $0.77. The company's market cap

Gainers Dyadic International (NASDAQ:DYAI) shares rose 10.9% to $2.24 during Thursday's pre-market session. The company's market cap stands at $64.5 million. MAIA Biotechnology (AMEX:MAIA) shares increased by 9.93% to $2.44. The market value of their outstanding shares is at $33.3 million. KORU Medical Systems (NASDAQ:KRMD) shares increased by 8.95% to $2.92. The company's market cap stands at $133.2 million. Comera Life Sciences (NASDAQ:CMRA) shares rose 8.57% to $0.3. The company's market cap stands at $9.3 million. Nuwellis (NASDAQ:NUWE) shares rose 8.06% to $1.07. The company's market cap stands at $1.9 million. Xilio Therapeutics (NASDAQ:XLO) shares rose 8.0% to $2.16. The company

Gainers Bionomics (NASDAQ:BNOX) stock moved upwards by 24.0% to $3.46 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 85.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $28.2 million. Oragenics (AMEX:OGEN) shares increased by 21.54% to $3.61. This security traded at a volume of 308.9K shares come close, making up 2992.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $9.1 million. Syndax Pharmaceuticals (NASDAQ:SNDX) stock moved upwards by 15.15% to $16.72. Trading volume for this security closed at 79.